Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear receptor-interacting protein 3 (NRIP3)
- Target
- NRIP3
- Molecular classification
- Other, Nuclear receptor co-regulator, Predicted aspartic-type endopeptidase
01
Overview
Nuclear receptor-interacting protein 3 (NRIP3) is a modulatory protein that interacts with nuclear receptors to regulate transcriptional programs affecting cellular metabolism, differentiation, and stress responses. NRIP3 is predicted to have aspartic-type endopeptidase activity and plays a role in proteolysis. Its overexpression is linked to increased tumor cell growth and resistance to chemoradiotherapy in esophageal squamous cell carcinoma, partly via the PPARα-DDI1-RTF2 axis, which protects cells from DNA damage-induced stress. NRIP3 is also suggested as a biomarker for aggressive cancer phenotypes and poor prognosis, and may contribute to metabolic and inflammatory disease pathways[1][2][4][5].
- Other names
- NY-SAR-105C11orf14Sarcoma antigen NY-SAR-105
02
Mechanism of action
Modulation of nuclear receptor-mediated transcription; Regulation of proteasomal function and replication stress response via DDI1 and PPARα signaling[2]
03
Biological functions
Regulation of transcriptionModulation of nuclear receptor signalingProteolysisCellular metabolismCellular stress responseCell proliferationResistance to apoptosisDNA damage response
04
Disease associations
CancerTumor progressionChemoradiotherapy resistanceLeukemiaPoor cancer prognosisPotential metabolic and inflammatory association
05
Safety considerations
Potential therapeutic challenges include targeting a molecule involved in stress adaptation and survival, which may lead to resistance mechanisms and off-target effects in non-tumor tissues
06
Interacting drugs
MK-886 (PPARα antagonist, used experimentally to modulate NRIP3-related pathways)[2]
07
Biomarkers
Elevated NRIP3 expression is a negative prognostic factor in esophageal squamous cell carcinoma (ESCC) and correlates with resistance to chemoradiotherapy[2]
Beyond the preview
Go deeper on Nuclear receptor-interacting protein 3 (NRIP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear receptor-interacting protein 3 (NRIP3).